Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?

TheMotleyFool

0 0

Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?

Exelixis (NASDAQ: EXEL) recently reported bad news from a late-stage study evaluating a combination of Cabometyx with Tecentriq in treating liver cancer. The biotech stock immediately sank close to 20%. In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Exelixis stock could be a buy after this clinical setback.

Source Fool.com

Like: 0

EXEL

Share